• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Tokai Pharmaceuticals

edit

Tokai was founded by Apple Tree Partners to in-license and develop endocrine-based therapies for major diseases.

The company’s primary focus is on its proprietary Specific Androgen Receptor Modulator/Lyase Inhibitor (TOK-001) for Castration Resistant Prostate Cancer (CRPC).

Recent Milestones

edit

• 
  Tokai Pharmaceuticals received $20M in Partial Close funding. (5/15/13)
  Posted 5/27/13 at 3:20am via sec.gov
• 
  Tokai Pharmaceuticals received $35.5M in Series E funding. (5/15/13)
  Posted 5/15/13 at 10:46pm via fiercebiotech.com
• 
  Tokai Pharmaceuticals received $23M in Series D funding. (9/20/11)
  Posted 9/20/11 at 4:53am via businesswire.com
• 
  Tokai Pharmaceuticals received $22M in Series D funding. (6/9/09)
  Posted 6/17/09 at 1:00pm via onbiovc.com
• 
  Tokai Pharmaceuticals added Seth Harrison as Board of Directors.
  Posted 6/17/09 at 1:00pm
• 
  Tokai Pharmaceuticals added Martin D. Williams as President and CEO.
  Posted 9/20/11 at 6:24pm
• 
  Tokai Pharmaceuticals added Jodie Morrison as CEO.
  Posted 9/20/11 at 6:24pm

Videos

Screenshots

edit

Above: Tokai Pharmaceuticals Screenshot -- #1
Uploaded: 6/17/09

Sources

1. Tokai Pharmaceuticals, Inc.: Series D $22M (onbiovc.com) [edit]
2. Tokai Pharmaceuticals Raises $23 Million in Funding (eon.businesswire.com) [edit]
3. Tokai lands $35M venture round for triple-threat prostate cancer drug (fiercebiotech.com) [edit]
4. SEC (sec.gov) [edit]